ArticleBioMedicine2024
Artificial intelligence-driven prediction and validation of blood-brain barrier permeability and absorption, distribution, metabolism, excretion profiles in natural product research laboratory compounds.
Article in BioMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A‑iMPO: A Design-Time Prediction Toolbox for Blood Brain Barrier Permeation Using an Integrated and Interpretable Multiparameter Optimization Framework.ACS medicinal chemistry letters · 2026Article
- Artificial intelligence revolutionizing CNS drug discovery and development.Drug discovery today · 2026Review
- Antcin K suppresses proinflammatory cytokines expression via the PI3K, Akt and NF-κB pathways in human gingival fibroblasts: implications for periodontitis treatment.Cell death discovery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Our previous research demonstrated that a large language model (LLM) based on the transformer architecture, specifically the MegaMolBART encoder with an XGBoost classifier, effectively predicts the blood-brain barrier (BBB) permeability of compounds. However, the permeability coefficients of compounds that can traverse this barrier remain unclear. Additionally, the absorption, distribution, metabolism, and excretion (ADME) characteristics of substances obtained from the Natural Product Research Laboratory (NPRL) at China Medical University Hospital (CMUH) have not yet been determined. Objectives: The study aims to investigate the pharmacokinetic ADME properties and BBB permeability coefficients of NPRL compounds. Materials and methods: A combined model using a transformer-based MegaMolBART encoder and XGBoost classifier was employed to predict BBB permeability. Machine learning (ML) tools from Discovery Studio were used to assess the ADME characteristics of the NPRL compounds. The CCK-8 assay was conducted to evaluate the cytotoxic effects of NPRL compounds on bEnd.3 brain endothelial cells after exposure to 10 μg/mL of the compounds. We assessed the permeability coefficient by subjecting bEnd.3 cell monolayers to the test compounds and measuring the permeability of FITC-dextran. Results: There were 4956 compounds that could cross the blood-brain barrier (BBB+) and 2851 that could not (BBB-) in the B3DB dataset that was utilized for training. A total of 2461 BBB+ and 2184 BBB- compounds were used in the NPRL-CMUH dataset for testing. The permeability coefficient of temozolomide (TMZ) and 21 other BBB + compounds exceeded 10 × 10 Conclusion: Computer-based predictions for the NPRL of CMUH compounds regarding their capacity to traverse the BBB are verified by the findings. Artificial intelligence (AI) prediction models have effectively identified the potential ADME characteristics of various compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.